Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana
Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the Japanese pharma. Kite, a unit of Gilead Sciences Inc. (NASDAQ:GILD), announced early this month that Frank Neumann would succeed Takeshita.
Next stop, IPO? A month after raising $100 million in a series C round from a deep-pocketed syndicate that includes BlackRock and RA Capital, TScan Therapeutics Inc. has hired Wall Street veteran Brian Silver as CFO, effective May 2. Silver will join the engineered T cell receptor (TCR) company from Freeline Therapeutics, where he serves as CFO and head of corporate development. Before joining Freeline in 2018, Silver was partner and head of biotechnology in Perella Weinberg Partners’ healthcare practice and managing director in Morgan Stanley’s healthcare investment banking group...